{"doi":"10.1002/9781119220787.ch120","title":"NORVIR (Ritonavir)","abstract":null,"journal":"Antibiotics Manual","year":2017,"id":611765,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"NORVIR (Ritonavir)","abstract":"This chapter provides the basic characteristics, side effects/toxicity, drug interactions, and dosage information of the norvir (ritonavir). Ritonavir reversibly binds the active site of the enzyme protease. Inhibition of protease prevents cleavage of the gag and gag-pol polyprotein, resulting in the production of immature, non-infectious virus. Development of mutations on the enzyme protease causes a conformational change that prevents ritonavir from binding the active site, allowing protease activity to continue. Ritonavir is metabolized by the liver. Ritonavir tablets should be taken with a meal; ritonavir capsules may be taken with or without meals. Ritonavir is an inhibitor of the CYP3A enzyme; coadministration of ritonavir and drugs primarily metabolized by CYP3A may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects. It is supplied as a 100 mg tablet and a liquid containing 600 mg/7.5 mL.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"23304386","pmcid":null,"openalex_id":"https://openalex.org/W4242958541","authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F9781119220787.ch120","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/9781119220787.ch120","host_type":"publisher"},{"url":"https://doi.org/10.1002/9781119220787.ch120","host_type":""}],"fields_of_study":["Drug-Induced Hepatotoxicity and Protection","Pharmacogenetics and Drug Metabolism","Hepatitis C virus research"],"mesh_terms":[],"keywords":["Ritonavir","Protease","Chemistry","CYP3A","Enzyme","Pharmacology","Protease inhibitor (pharmacology)","Biochemistry","Virology","Biology","Virus","Microsome","Viral load"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-01T22:23:49.612390Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}